Protara Therapeutics (TARA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$21.7M

Net income growth (year over year)

−44.84%

Net margin

—

Return on equity

−45.80%

EPS (trailing twelve months)

−$1.36

Book value per share

$2.73

P/E (trailing twelve months)

—

Price to book

0.91

Debt to assets

8.39%

Payout ratio

—

Dividend yield

—

Company profile

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

• How do I buy stock in Protara Therapeutics (TARA)?

  TARA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.